Eicosanoids, leukocytes and lung injury.
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000707:Anaphylaxis / Q000503:physiopathology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002396:Catechols / Q000494:pharmacology; D003167:Complement Activation; D003165:Complement System Proteins / Q000276:immunology*; D016861:Cyclooxygenase Inhibitors; D005609:Free Radicals; D007958:Leukocyte Count; D016859:Lipoxygenase Inhibitors; D008208:Lymphatic System / Q000187:drug effects; D009637:Masoprocol; D008469:Meclofenamic Acid / Q000494:pharmacology; D010100:Oxygen / Q000097:blood; D013482:Superoxide Dismutase / Q000378:metabolism; D013929:Thromboxane B2 / Q000097:blood
D002396:Catechols; D016861:Cyclooxygenase Inhibitors; D005609:Free Radicals; D016859:Lipoxygenase Inhibitors; D008469:Meclofenamic Acid; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D009637:Masoprocol; D003165:Complement System Proteins; D013482:Superoxide Dismutase; D010100:Oxygen